Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 06/04/25
End: 10/31/27
Due: 10/31/28
Phase: N/A
Priority: Normal
Start: 04/29/24
End: 06/30/28
Due: 06/30/29
Phase: N/A
Priority: Normal
Start: 05/14/25
End: 12/31/29
Due: 12/31/30
Phase: N/A
Priority: Normal
Start: 03/27/25
End: 03/31/27
Due: 03/31/28
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis | NCT07027527 | Apogee Therapeutics, Inc. | user2@example.com | None | 2025-06-04 | 2027-10-31 | 2028-10-31 | - | - | 2025-07-14 |
| A Study Evaluating APG777 in Atopic Dermatitis | NCT06395948 | Apogee Therapeutics, Inc. | user2@example.com | None | 2024-04-29 | 2028-06-30 | 2029-06-30 | - | - | 2025-07-14 |
| A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis | NCT07003425 | Apogee Therapeutics, Inc. | user2@example.com | None | 2025-05-14 | 2029-12-31 | 2030-12-31 | - | - | 2025-07-14 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma | NCT06920901 | Apogee Therapeutics, Inc. | user2@example.com | None | 2025-03-27 | 2027-03-31 | 2028-03-31 | - | - | 2025-07-14 |